

In the Claims:

1. (currently amended) A method for treating unstable or overactive urinary bladder in a mammal, said method comprising orally administering to a mammal a pharmaceutically effective dose of an antimuscarinic agent ~~when~~ on an as needed (prn) basis, whereby a symptomatic relief of urgency and/or frequency is achieved.

2. (previously presented) The method as claimed in claim 1, wherein the antimuscarinic agent is one or more compounds selected from tolterodine, a racemate to tolterodine, the corresponding (S)-enantiomer to tolterodine, the 5-hydroxymethyl metabolite of said (S)-enantiomer to tolterodine, fesoterodine, or a pharmaceutically acceptable salt of said racemate, (S)-enantiomer, 5-hydroxymethyl metabolite of said (S)-enantiomer to tolterodine, or fesoterodine.

3. (previously presented) The method according to claim 2, wherein the compound is tolterodine or a pharmaceutically acceptable salt thereof.

4. (canceled)

5. (previously presented) The method according to claim 1, wherein the mammal is human.

6. (previously presented) The method according to claim 5, wherein the pharmaceutically effective dose is 2 mg or 4 mg

of the antimuscarinic agent, administered as a controlled release tablet or capsule.

7. (previously presented) The method according to claim 5, wherein two pharmaceutically effective doses of the antimuscarinic agent are administered daily at an interval of 8-12 hours.

8. (previously presented) The method according to claim 7, wherein the pharmaceutically effective dose is 1 mg of the antimuscarinic agent, administered as an immediate release tablet or capsule.

9. (previously presented) The method according to claim 7, wherein the pharmaceutically effective dose is 1 mg or 2 mg of the antimuscarinic agent, administered as a controlled release tablet or capsule.

10. (currently amended) The method according to claim 7, wherein the pharmaceutically effective doses of the antimuscarinic agent are taken within the interval of 8 hours.

11. (currently amended) The method according to claim 7, wherein the pharmaceutically effective doses of the antimuscarinic agent are taken within the interval of 9 hours.

12. (currently amended) The method according to claim 7, wherein the pharmaceutically effective doses of the antimuscarinic agent are taken within the interval of 10 hours.

13. (currently amended) The method according to claim 7, wherein the pharmaceutically effective doses of the antimuscarinic agent are taken within the interval of 11 hours.

14. (currently amended) The method according to claim 7, wherein the pharmaceutically effective doses of the antimuscarinic agent are taken within the interval of 12 hours.

15. (canceled)